BioCentury | Dec 19, 2018
Distillery Therapeutics

Hematology

...component of clots, the compound decreased fibrin degradation compared with the serine protease inhibitor Trasylol aprotinin...
...include testing the compound in animal models of bleeding. Bayer AG and Nordic Group market Trasylol...
BioCentury | Sep 28, 2015
Emerging Company Profile

Microparticle man

...without instigating unwanted coagulation. Available hemostatics used for acute bleeding pose significant safety risks. Trasylol aprotinin...
BioCentury | Jun 5, 2014
Distillery Techniques

Technology: Drug delivery

...segment that binds fibrin plus a second fusion protein made up of the fibrinolysis inhibitor aprotinin...
BioCentury | Jul 23, 2012
Company News

Nordic Group, Bayer sales and marketing update

...Bayer's Bayer HealthCare subsidiary granted Nordic Group worldwide rights to Trasylol aprotinin outside the U.S. Details...
...Details were not disclosed. Earlier this year, EMA's CHMP recommended lifting the marketing suspension of Trasylol...
...that the data on which the suspension was based were "unreliable." The committee concluded that Trasylol's...
BioCentury | Feb 27, 2012
Clinical News

Trasylol aprotinin regulatory update

...EMA's CHMP recommended lifting the marketing suspension of Bayer's Trasylol aprotinin in the EU following a...
...patients given Trasylol vs. antifibrinolytics, epsilon-aminocaproic acid or tranexamic acid (see BioCentury, Nov. 12, 2007). Trasylol...
...course of coronary artery bypass graft (CABG) surgery. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Trasylol aprotinin...
BioCentury | Feb 8, 2010
Strategy

Spending for a rainy day

...the compound could help fill the void left by Bayer AG 's withdrawal of Trasylol aprotinin...
...from the market, which created a need for a drug with titratable and predictable properties. Trasylol...
...that its BART trial was halted because of higher mortality among cardiac surgery patients given Trasylol...
BioCentury | May 19, 2008
Company News

Bayer sales and marketing update

...Bayer notified FDA of plans to withdraw all remaining supplies of Trasylol aprotinin from hospital pharmacies...
...data from the Canadian BART trial in The New England Journal of Medicine. Access to Trasylol...
...trial was halted because of higher mortality among cardiac surgery patients given Trasylol vs. antifibrinolytics. Trasylol...
BioCentury | Feb 20, 2008
Politics & Policy

House subcommittee to hold drug safety hearing

...related to Trasylol aprotinin from Bayer (FSE:BAY). Last year, the company suspended worldwide marketing of Trasylol...
BioCentury | Jan 7, 2008
Finance

4Q approvals

...atherosclerosis in coronary artery disease (CAD) patients Bayer (FSE:BAY) Temporarily suspends worldwide marketing of Trasylol aprotinin...
...professionals after the Canadian BART trial was stopped because of higher mortality in patients given Trasylol...
BioCentury | Nov 12, 2007
Company News

Bayer sales and marketing update

...BAY will temporarily suspend worldwide marketing of Trasylol aprotinin at the request of regulatory agencies in...
...professionals after the Canadian BART trial was stopped because of higher mortality in patients given Trasylol...
...regulatory authorities that wish to create a program under which physicians might request and receive Trasylol...
Items per page:
1 - 10 of 47